Document Detail

An integrated alcohol abuse and medical treatment model for patients with hepatitis C.
MedLine Citation:
PMID:  22134784     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment.
AIMS: This prospective cohort study examined the feasibility of a 24-week integrated alcohol and medical treatment to HCV-infected patients.
METHODS: Patients were recruited from a hepatology clinic if they had an Alcohol Use Disorders Identification Test score >4 for women and >8 for men, suggesting hazardous alcohol consumption. The integrated model included patients receiving medical care and alcohol treatment within the same clinic. Alcohol treatment consisted of 6 months of group and individual therapy from an addictions specialist and consultation from a study team psychiatrist as needed.
RESULTS: Sixty patients were initially enrolled, and 53 patients participated in treatment. The primary endpoint was the Addiction Severity Index (ASI) alcohol composite scores, which significantly decreased by 0.105 (41.7% reduction) between 0 and 3 months (P < 0.01) and by 0.128 (50.6% reduction) between 0 and 6 months (P < 0.01) after adjusting for covariates. Alcohol abstinence was reported by 40% of patients at 3 months and 44% at 6 months. Patients who did not become alcohol abstinent had reductions in their ASI alcohol composite scores from 0.298 at baseline to 0.219 (26.8% reduction) at 6 months (P = 0.08).
CONCLUSION: This study demonstrated that an integrated model of alcohol treatment and medical care could be successfully implemented in a hepatology clinic with significant favorable impact on alcohol use and abstinence among patients with chronic HCV.
Rae Jean Proeschold-Bell; Ashwin A Patkar; Susanna Naggie; Lesleyjill Coward; Paolo Mannelli; Jia Yao; Patricia Bixby; Andrew J Muir
Related Documents :
14599834 - Trigger thumb: results of a prospective randomised study of percutaneous release with s...
16714924 - Myobloc for the treatment of benign essential blepharospasm in patients refractory to b...
736584 - Treatment of keratoacanthomas with intralesional fluorouracil.
18359354 - Botulinum toxin for radiation-induced facial pain and trismus.
16412854 - Transcatheter closure of perimembranous ventricular septal defects using the new amplat...
22032214 - Long-term outcome poststroke: predictors of activity limitation and participation restr...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural     Date:  2011-12-02
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  57     ISSN:  1573-2568     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-19     Completed Date:  2012-05-07     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1083-91     Citation Subset:  AIM; IM    
Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, 2812 Erwin Rd., #403, Durham, NC 27705, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alcoholism / complications,  therapy*
Hepatitis C, Chronic / complications,  drug therapy*
Middle Aged
Patient Care Team*
Psychotherapy, Group
Grant Support

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastas...
Next Document:  Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-r...